LYEL
NASDAQLyell Immunopharma Inc.
Price$12.78-0.25 (-1.92%)
01:30 PM05:15 PM
News · 26 weeks43-57%
2025-12-072026-05-31
Mix2490d
- SEC Filings10(42%)
- Other5(21%)
- Insider4(17%)
- Analyst3(13%)
- Offering1(4%)
- Leadership1(4%)
Latest news
25 items- PRLyell Immunopharma Announces Participation in Goldman Sachs 47th Annual Global Healthcare Conference 2026SOUTH SAN FRANCISCO, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (NASDAQ:LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, today announced that members of its senior management team will participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026 on Monday, June 8, 2026, in Miami, Florida, with a fireside chat scheduled for 11:20 am Eastern Time. A live webcast of the fireside chat and subsequent replay can be accessed through the Investors section of the Company's website at www.lyell.com. About Lyell Immunopharma, Inc. Lyell is a late-stage cl
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Lyell Immunopharma Inc.SCHEDULE 13G/A - Lyell Immunopharma, Inc. (0001806952) (Subject)
- PRLyell Immunopharma Announces Participation in May Investor ConferencesSOUTH SAN FRANCISCO, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (NASDAQ:LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, today announced that members of its senior management team will participate in the following investor conferences: H.C. Wainwright 4th Annual BioConnect Investor Conference on Tuesday, May 19, 2026, in New York City, New York; fireside chat at 11:00 am Eastern Time2026 Stifel Virtual Targeted Oncology Forum on Wednesday, May 20, 2026; fireside chat at 4:00 pm Eastern Time A live webcast of each fireside chat can be accessed through the Investors
- SECSEC Form 10-Q filed by Lyell Immunopharma Inc.10-Q - Lyell Immunopharma, Inc. (0001806952) (Filer)
- SECLyell Immunopharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Lyell Immunopharma, Inc. (0001806952) (Filer)
- PRLyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2026PiNACLE pivotal clinical trial evaluating ronde-cel in patients with LBCL in third- or later-line setting on track to report additional data in second half of 2026, with pivotal data expected mid-2027 and BLA submission expected to follow in 2027PiNACLE-H2H, a first of its kind Phase 3 clinical trial evaluating ronde-cel head-to-head against standard-of-care CD19 CAR T-cell therapies in the LBCL second-line setting, commenced patient dosingPhase 1 clinical trial of LYL273 continues to enroll patients with metastatic colorectal cancer, with commencement of patient dosing at Dose Level 3Closed second $50 million tranche of $100 million private placement at $25.61 per share, with approximately
- ANALYSTRobert W. Baird initiated coverage on Lyell Immunopharma with a new price targetRobert W. Baird initiated coverage of Lyell Immunopharma with a rating of Outperform and set a new price target of $49.00
- SECSEC Form DEFA14A filed by Lyell Immunopharma Inc.DEFA14A - Lyell Immunopharma, Inc. (0001806952) (Filer)
- SECSEC Form DEF 14A filed by Lyell Immunopharma Inc.DEF 14A - Lyell Immunopharma, Inc. (0001806952) (Filer)
- SECSEC Form EFFECT filed by Lyell Immunopharma Inc.EFFECT - Lyell Immunopharma, Inc. (0001806952) (Filer)
- ANALYSTNeedham initiated coverage on Lyell Immunopharma with a new price targetNeedham initiated coverage of Lyell Immunopharma with a rating of Buy and set a new price target of $44.00
- PRLyell Immunopharma Announces Participation in 25th Annual Needham Virtual Healthcare ConferenceSOUTH SAN FRANCISCO, Calif., April 07, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (NASDAQ:LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, today announced that members of its senior management team will present and participate in the 25th Annual Needham Virtual Healthcare Conference on Tuesday, April 14, 2026, at 11:00 am Eastern Time. A live webcast of the presentation can be accessed through the Investors section of the Company's website at www.lyell.com. A replay of the webcast will be available on the Company's website following the presentation date. About Lyell Lyell is a
- SECSEC Form S-3 filed by Lyell Immunopharma Inc.S-3 - Lyell Immunopharma, Inc. (0001806952) (Filer)
- INSIDERSEC Form 4 filed by Chief Fin. and Bus. Officer Shah Smital4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
- INSIDERSEC Form 3 filed by new insider Shah Smital3 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
- SECSEC Form S-8 filed by Lyell Immunopharma Inc.S-8 - Lyell Immunopharma, Inc. (0001806952) (Filer)
- SECSEC Form 10-K filed by Lyell Immunopharma Inc.10-K - Lyell Immunopharma, Inc. (0001806952) (Filer)
- SECLyell Immunopharma Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Lyell Immunopharma, Inc. (0001806952) (Filer)
- PRLyell Immunopharma Reports Q4 and Full Year 2025 Business and Financial ResultsPatient dosing has commenced in first-of-its-kind Phase 3 head-to-head CAR T-cell 2L randomized controlled clinical trial (PiNACLE-H2H) in patients with large B-cell lymphoma, and the 3L+ pivotal trial (PiNACLE) evaluating ronde-cel is ongoingPhase 1 trial is ongoing for LYL273, an enhanced GCC-targeted CAR T-cell candidate for metastatic colorectal cancer; seven new patients treated without dose-limiting toxicity and including dose escalation to Dose Level 3Smital Shah was appointed Chief Financial and Business Officer in March 2026Second $50 million tranche of $100 million equity private placement closed in March 2026 after achievement of clinical milestone for ronde-celCash of approximate
- INSIDERLarge owner Arch Venture Partners Ix, Llc bought $12,499,985 worth of shares (488,090 units at $25.61) (SEC Form 4)4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
- INSIDERLarge owner Arch Venture Fund Xiii, L.P. bought $12,499,985 worth of shares (488,090 units at $25.61) (SEC Form 4)4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
- ANALYSTCitizens initiated coverage on Lyell Immunopharma with a new price targetCitizens initiated coverage of Lyell Immunopharma with a rating of Mkt Outperform and set a new price target of $34.00
- SECSEC Form 8-K filed by Lyell Immunopharma Inc.8-K - Lyell Immunopharma, Inc. (0001806952) (Filer)
- PRLyell Immunopharma Announces Closing of Additional $50 Million Tranche of Equity Private Placement and Appointment of Smital Shah as Chief Financial and Business OfficerClosing of additional $50 million tranche of $100 million equity private placement after achievement of clinical milestone for rondecabtagene autoleucelSmital Shah appointed Chief Financial and Business Officer SOUTH SAN FRANCISCO, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (NASDAQ:LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, today announced it has closed the sale of an additional $50 million of shares of its common stock to investors from its July 2025 equity private placement of up to $100 million, following achievement of a clinical milestone within its Pi
- PRLyell Immunopharma Announces Participation in March Investor ConferencesSOUTH SAN FRANCISCO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (NASDAQ:LYEL), a clinical-stage company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, today announced that members of its senior management team will present and participate in the following investor conferences: TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026, in Boston, Massachusetts; presentation at 9:10am Eastern TimeLeerink Annual Global Healthcare Conference on Monday, March 9, 2026, in Miami, Florida; fireside chat at 10:00am Eastern TimeCitizens Life Science Conference on Tuesday, March 10, 2026, in Miami,
LYEL FAQ
7 questionsWhat does Lyell Immunopharma Inc. do?
Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers; LYL845 for multiple solid tumors; and NY-ESO-1 for synovial...Where does LYEL stock trade?
Lyell Immunopharma Inc. (LYEL) is listed on NASDAQ.What sector and industry is LYEL in?
Lyell Immunopharma Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Lyell Immunopharma Inc. go public?
Lyell Immunopharma Inc. (LYEL) completed its IPO in 2021.What are analysts saying about LYEL?
Lyell Immunopharma Inc. has had 8 recent analyst actions on file. The most recent action was from Robert W. Baird: Outperform with a $4900.00 price target on 2026-05-01.What companies are similar to LYEL?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare LYEL side-by-side with any of them on Quantisnow.How can I track LYEL on Quantisnow?
Quantisnow aggregates Lyell Immunopharma Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow LYEL to receive live email and push alerts on every new disclosure.